REGN vs INCY

For growth investors, Incyte Corporation (INCY) is the stronger pick with 21.

2% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Incyte Corporation (INCY) offers the better valuation at 15. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate Regeneron Pharmaceuticals, Inc. (REGN) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Incyte Corporation (INCY) is the cheapest at 15.

6x versus Regeneron Pharmaceuticals, Inc. at 17. 4x. On forward P/E, Incyte Corporation is actually cheaper at 13. 3x.

Over the past 5 years, Regeneron Pharmaceuticals, Inc.

(REGN) delivered a total return of +45. 4%, compared to +21. 3% for Incyte Corporation (INCY). Over 10 years, the gap is even starker: REGN returned +96. 0% versus INCY's +41. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc.

(REGN) is the lower-risk stock at 0. 81β versus Incyte Corporation's 0. 87β — meaning INCY is approximately 9% more volatile than REGN relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 9% for Regeneron Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Incyte Corporation (INCY) is pulling ahead at 21.

2% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Incyte Corporation grew EPS 41. 7% year-over-year, compared to 8. 2% for Regeneron Pharmaceuticals, Inc.. Over a 3-year CAGR, INCY leads at 14. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus 25. 0% for Incyte Corporation — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INCY leads at 26. 1% versus 24. 9% for REGN. At the gross margin level — before operating expenses — INCY leads at 91. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Incyte Corporation (INCY) trades at 13.

3x forward P/E versus 15. 6x for Regeneron Pharmaceuticals, Inc. — 2. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for REGN: 20. 1% to $865. 68.

In this comparison, REGN (0.

5% yield) pays a dividend. INCY does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc.

(REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 81)). Both have compounded well over 10 years (REGN: +96. 0%, INCY: +41. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: REGN is a mid-cap deep-value stock; INCY is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.